Overview
Bioton is a Polish biotechnology company that specializes in the development and production of biopharmaceuticals, particularly insulin for diabetes treatment. They provide a platform for patients to receive expert education and support regarding diabetes management. Their modern factory in Macierzysz, near Warsaw, is equipped with advanced technology for the synthesis and production of insulin.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 3.82
- High
- PLN 3.82
- Low
- PLN 3.77
- Volume
- 11.01K
- Avg. vol.
- 54.73K
- Market cap
- PLN 323.71M
- P/E ratio
- –
- EPS
- -PLN 0.10
- Shares outstanding
- 85.86M
- 52-week
- PLN 3.63 – 3.98
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLBIOTN00029
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 19.19m | USD -2.80m | USD -2.48m |
| Q1 2026 | USD 13.27m | USD -1.09m | USD -1.39m |
| Q4 2025 | USD 16.17m | USD 967.86k | USD 442.49k |
| Q3 2025 | USD 18.25m | USD 1.83m | USD 1.05m |
Results for Q3 2026:Nov 10, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 1993-07-05. Active
18 1020 1026 0000 1102 0442 1236
21 1050 1025 1000 0024 1417 0437- 47 1020 1026 0000 1802 0442 1244
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 28, 2026 | Call to creditors |
Public aid
10 public aid cases recorded, with a total value of $9,080,083.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 25, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Towarzystwo Inwestycji Społeczno-Ekonomicznych S.A. | |
| Dec 23, 2024 | Aid to cover additional costs related to an exceptionally significant increase in natural gas and electricity prices as a result of the war in Ukraine | –– | Prezes Zarządu Narodowego Funduszu Ochrony Środowiska i Gospodarki Wodnej | |
| Mar 21, 2024 | Aid to cover additional costs related to an exceptionally significant increase in natural gas and electricity prices as a result of the war in Ukraine | –– | Prezes Zarządu Narodowego Funduszu Ochrony Środowiska i Gospodarki Wodnej |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-08-24 | Opracowanie innowacyjnej technologii wytwarzania krótko i długodziałających analogów insuliny mających zastosowanie w terapii cukrzycy. | $5.3M$5,322,824 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Trademarks
Bioton holds 77 active trademarks registered with the Polish Patent Office. 35 marks have expired or were not registered. The first mark was filed in 1993.
| Mark | Protected until | |
|---|---|---|
| Gensucare v(word) | Dec 2, 2031 | |
| Combodiab(word) | Jul 30, 2029 | |
| Depediab(word) | Jul 30, 2029 | |
| BIOTON | Apr 3, 2028 | |
| GensuFine(word) | Aug 3, 2027 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
If the management board is a one-person management board, the company is represented by one member of the management board. If the management board is a multi-member management board, the company is represented by two members of the management board acting jointly or one member of the management board acting jointly with a commercial proxy.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Bioton.
Capital group
| Name | Ownership |
|---|---|
Informacje ogólne o Biolek Sp. z o.o  | 10% |
PODSTAWOWE INFORMACJE DOTYCZĄCE SPÓŁKI ORAZ GRUPY KAPITAŁOWEJ BIOTON S.A | 9% |
Skład Zarządu i Rady Nadzorczej Bioton S.A | 9% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Adamed PharmaS.A. | $541,927,181.76 | adamed.com.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| ICN Polfa RzeszówS.A. | $85,044,250.03 | icnpolfa.pl | ||
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A. | $37,103,878.54 | biomed.pl | ||
| VipharmS.A. | $30,660,173.61 | vipharm.pl | ||
| Przedsiębiorstwo Farmaceutyczne Farmapolsp. z o.o. | $21,462,728.43 | farmapol.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-08-21 | Share capital change (1,717,284,000.00 PLN → 8,586,420.00 PLN) | |
| 2026-07-21 | PKD change (Removed: 72.11.Z, 72.19.Z, 86.90.E; Added: 32.50.B, 72.10.Z, 86.99.D) | |
| 2026-04-27 | Address change (Starościńska 5, 02-516, Warszawa → Ul. Poznańska 12, 05-850, Macierzysz) | |
| 2019-11-25 | PKD change (Removed: 85.60.Z; Added: 72.11.Z) | |
| 2015-07-09 | PKD change (Removed: 10.89.Z, 18.12.Z, 20.20.Z, 20.41.Z, 20.42.Z, 26.60.Z, 28.25.Z, 31.01.Z, 32.50.Z, 33.12.Z, 33.20.Z, 36.00.Z, 37.00.Z, 38.11.Z, 38.12.Z, 38.21.Z, 38.22.Z, 46.38.Z, 46.45.Z, 46.75.Z, 47.73.Z, 47.74.Z, 47.75.Z, 58.11.Z, 58.13.Z, 58.14.Z, 58.19.Z, 59.20.Z, 68.10.Z, 68.20.Z, 69.20.Z, 70.22.Z, 71.11.Z, 71.12.Z, 73.11.Z, 73.20.Z, 74.90.Z, 77.11.Z, 82.11.Z, 82.19.Z, 82.91.Z, 82.99.Z, 85.59.B) |
FAQ
Last updated: 2026-10-03